自拟止血复元中药免煎颗粒治疗创伤性凝血病的临床研究
|
摘要
目的观察自拟止血复元中药免煎颗粒治疗创伤性凝血病(ATC)的临床疗效。方法 ATC患者66例按就诊顺序随机分为两组,西药组给予西医常规综合疗法进行治疗,中药组在西药组治疗的基础上,再加入自拟止血复元中药免煎颗粒进行治疗;两组治疗均7 d为1个疗程。结果从凝血功能、循环功能、炎性因子水平、血制品用量、不良事件发生情况等几方面比较,中药组均优于西药组(P <0.05)。结论采用自拟止血复元中药免煎颗粒治疗ATC的临床应用疗效显著。
Objective: To investigate the clinical efficacy of Self-made TCM Decoction-free Granules for Hemostasis and Recovery on ATC. Methods: 66 patients were randomly divided into TCM group and WM group according to the order of treatment,33 cases in each. WM group received routine treatment;TCM group added Self-made TCM Decoction-free Granules for Hemostasis and Recovery. The treatment course was 7 days. Results: Compared with WM group,TCM group was superior in terms of coagulation function,circulatory function,levels of inflammatory factors,dosage of blood products and occurrence of adverse events(P < 0.05). Conclusion:Self-made TCM Decoction-free Granules for Hemostasis and Recovery has a significant clinical efficacy on ATC.
Objective: To investigate the clinical efficacy of Self-made TCM Decoction-free Granules for Hemostasis and Recovery on ATC. Methods: 66 patients were randomly divided into TCM group and WM group according to the order of treatment,33 cases in each. WM group received routine treatment;TCM group added Self-made TCM Decoction-free Granules for Hemostasis and Recovery. The treatment course was 7 days. Results: Compared with WM group,TCM group was superior in terms of coagulation function,circulatory function,levels of inflammatory factors,dosage of blood products and occurrence of adverse events(P < 0.05). Conclusion:Self-made TCM Decoction-free Granules for Hemostasis and Recovery has a significant clinical efficacy on ATC.
引文
[1]尹文,李俊杰.急性创伤性凝血病的研究进展[J].创伤外科杂志,2014,16(3):197-200.
[2] Maegele M. Coagulopathy after traumatic brain injury:incidence,pathogenesis,and treatment options[J]. Transfusion,2013,53(S1):28-37.
[3] Palmer L,Martin L. Traumatic coagulopathy-part 1:Pathophysiology and diagnosis[J]. J Vet Emerg Crit Care,2014,24(1):63-74.
[4]马明远,江皓波,张云海,等.血必净注射液对创伤性凝血病患者血制品输注及炎症因子的影响[J].实用医学杂志,2015,36(20):3415-3418.
[5]陈小凤,阳文新,孙守松,等. ISS评分与CRAMS评分在多发伤患者预后评估中的应用[J].中华急诊医学杂志,2017,26(6):664-668.
[6]中国研究型医院学会卫生应急学专业委员会,中国中西医结合学会自然灾害医学专业委员会.急性创伤性凝血功能障碍与凝血病诊断和卫生应急处理专家共识(2016)[J].中华卫生应急电子杂志,2016,2(4):197-203.
[7]刘大为.实用重症医学[M]. 2版.北京:人民卫生出版社,2017:523-547.
[8] Spahn DR,Bouillon B,Cerny V,et al. Management of bleeding and coagulopathy following major trauma:an updated European guideline[J]. Crit Care,2013,17(2):R76.
[9]李红波,苏磊.创伤性凝血病与颅脑损伤的相关性分析[J].实用医学杂志,2013,29(5):782-784.
[10]秦娜,李无阴,魏立伟.血必净注射液对严重创伤患者T淋巴细胞亚群及炎性细胞因子的影响[J].中成药,2013,35(9):1879-1881.
[11]马明远,江皓波,徐杰,等.血必净注射液对创伤性凝血病患者凝血功能及微循环灌注的影响[J].实用医学杂志,2014,30(12):1993-1995.
[12]杨兴才,韦红,郑天虹,等.血必净注射液对脓毒症血管内皮损伤微循环障碍患者治疗及器官功能保护作用的临床研究[J].中国综合临床,2017,33(9):812-818.
[13]张伯礼,吴勉华.中医内科学(新4版)[M].北京:中国中医药出版社,2016,227-235.
[14]金兰.大黄的药理作用及临床应用进展[J].中国医药指南,2013,11(11):487-488.
[15]张来宾,吕洁丽,陈红丽,等.当归中苯酞类成分及其药理作用研究进展[J].中国中药杂志,2016,41(2):167-176.
[16]钟赣生.中药学[M]. 4版.北京:中国中医药出版社,2016:54-107.
[17]殷佳,潘晔,蔡雪朦,等.中药传统汤剂、浸膏剂和配方颗粒剂的比较[J].中草药,2017,48(18):3871-3875.
[2] Maegele M. Coagulopathy after traumatic brain injury:incidence,pathogenesis,and treatment options[J]. Transfusion,2013,53(S1):28-37.
[3] Palmer L,Martin L. Traumatic coagulopathy-part 1:Pathophysiology and diagnosis[J]. J Vet Emerg Crit Care,2014,24(1):63-74.
[4]马明远,江皓波,张云海,等.血必净注射液对创伤性凝血病患者血制品输注及炎症因子的影响[J].实用医学杂志,2015,36(20):3415-3418.
[5]陈小凤,阳文新,孙守松,等. ISS评分与CRAMS评分在多发伤患者预后评估中的应用[J].中华急诊医学杂志,2017,26(6):664-668.
[6]中国研究型医院学会卫生应急学专业委员会,中国中西医结合学会自然灾害医学专业委员会.急性创伤性凝血功能障碍与凝血病诊断和卫生应急处理专家共识(2016)[J].中华卫生应急电子杂志,2016,2(4):197-203.
[7]刘大为.实用重症医学[M]. 2版.北京:人民卫生出版社,2017:523-547.
[8] Spahn DR,Bouillon B,Cerny V,et al. Management of bleeding and coagulopathy following major trauma:an updated European guideline[J]. Crit Care,2013,17(2):R76.
[9]李红波,苏磊.创伤性凝血病与颅脑损伤的相关性分析[J].实用医学杂志,2013,29(5):782-784.
[10]秦娜,李无阴,魏立伟.血必净注射液对严重创伤患者T淋巴细胞亚群及炎性细胞因子的影响[J].中成药,2013,35(9):1879-1881.
[11]马明远,江皓波,徐杰,等.血必净注射液对创伤性凝血病患者凝血功能及微循环灌注的影响[J].实用医学杂志,2014,30(12):1993-1995.
[12]杨兴才,韦红,郑天虹,等.血必净注射液对脓毒症血管内皮损伤微循环障碍患者治疗及器官功能保护作用的临床研究[J].中国综合临床,2017,33(9):812-818.
[13]张伯礼,吴勉华.中医内科学(新4版)[M].北京:中国中医药出版社,2016,227-235.
[14]金兰.大黄的药理作用及临床应用进展[J].中国医药指南,2013,11(11):487-488.
[15]张来宾,吕洁丽,陈红丽,等.当归中苯酞类成分及其药理作用研究进展[J].中国中药杂志,2016,41(2):167-176.
[16]钟赣生.中药学[M]. 4版.北京:中国中医药出版社,2016:54-107.
[17]殷佳,潘晔,蔡雪朦,等.中药传统汤剂、浸膏剂和配方颗粒剂的比较[J].中草药,2017,48(18):3871-3875.